Millennium Says Heavy R&D Costs, Acquisition Fees Offset Strong Revenue Growth in Q3

Oct 15, 2002

NEW YORK, Oct. 15 - Millennium Pharmaceuticals today reported that a jump in R&D spending and the cost of acquiring Cor Therapeutics in February offset a surge in total revenue during the third quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

WHO Panel Announced

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

Research Reproducibility Scores

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

Tests for All Diagnosed

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

This Week in Science

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Main menu